NCT04146129View on ClinicalTrials.gov

A Phase 1 Study of CDX-0159

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

April 6, 2020

Study Completion Date

June 26, 2020

Conditions
Healthy Subjects
Interventions
DRUG

CDX-0159

Single dose of one of four dosages of CDX-0159

DRUG

Normal saline

Single infusion of normal saline

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT04146129 - A Phase 1 Study of CDX-0159 | Biotech Hunter | Biotech Hunter